Diagnostic challenges of kidney diseases in HIV-infected patients

References

• Smit M, Brinkman K, Geerlings S, et al.. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–818.
   PubMed Web of Science ®Google Scholar
• Schouten J, Wit FW, Stolte IG, et al.. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–1797.
   PubMed Web of Science ®Google Scholar
• Fabian J, Naicker S. HIV and kidney disease in sub-Saharan Africa. Nat Rev Nephrol. 2009;5(10):591–598..
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ryom L, Begovac J, et al. Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS. 2014;28(5):727–737.
   PubMed Web of Science ®Google Scholar
• Choi AI, Rodriguez RA, Bacchetti P, et al.. The impact of HIV on chronic kidney disease outcomes. Kidney Int. 2007;72(11):1380–1387.
   PubMed Web of Science ®Google Scholar
• Canaud G, Dejucq-Rainsford N, Avettand-Fenoël V, et al. The Kidney as a Reservoir for HIV-1 after Renal Transplantation. J Am Soc Nephrol. 2014;25(2):407–419.
   PubMed Web of Science ®Google Scholar
• Blasi M, Carpenter JH, Balakumaran B, et al.. Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. AIDS. 2015;29(13):1651–1657.
   PubMed Web of Science ®Google Scholar
• Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310(11):669–673.
   PubMed Web of Science ®Google Scholar
• Lescure F-X, Flateau C, Pacanowski J, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant. 2012;27(6):2349–2355.
   PubMed Web of Science ®Google Scholar
• Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol. 2008;28(3):478–486.
   PubMed Web of Science ®Google Scholar
• Waheed S, Atta MG. Predictors of HIV-associated nephropathy. Expert Rev Anti Infect Ther. 2014;12(5):555–563.
   PubMed Web of Science ®Google Scholar
• Rosenberg AZ, Naicker S, Winkler CA, et al.. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015 Mar;11(3):150–160.
   PubMed Web of Science ®Google Scholar
• Nobakht E, Cohen SD, Rosenberg AZ, et al.. HIV-associated immune complex kidney disease. Nat Rev Nephrol. 2016 May;12(5):291–300.
   PubMed Web of Science ®Google Scholar
• Campos P, Ortiz A, Soto K. HIV and kidney diseases: 35 years of history and consequences. Clin Kidney J. 2016;9(6):772–781.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Nóvoa S, Alvarez E, Labarga P, et al.. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010 Jul 9;(4):545–559.
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al.. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689–696.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Labarga P, D’avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24(7):1064–1066.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics. 2009;10(10):1675–1685.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48(11):e108–16.
   PubMed Web of Science ®Google Scholar
• Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011;204(1):145–153.
   PubMed Web of Science ®Google Scholar
• Quesada PR, Esteban LL, García JR, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37(5):865–872.
   PubMed Web of Science ®Google Scholar
• Jose S, Hamzah L, Campbell LJ, et al. Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure. J Infect Dis. 2014;210(3):363–373.
   PubMed Web of Science ®Google Scholar
• Imaz A, Podzamczer D. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Rev Anti Infect Ther. 2017;15(3):195–209.
   PubMed Web of Science ®Google Scholar
• Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–58.
   PubMedGoogle Scholar
• Post FA, Yazdanpanah Y, Schembri G, et al. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial(). HIV Clin Trials. 2017;18(3):135–140.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Lundgren JD, Ross M, et al.. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23–32.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Lundgren JD, Ross M, et al.. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLOS Med. 2015;12(3):e1001809.
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21(7):1377–1382.
   PubMed Web of Science ®Google Scholar
• Medapalli RK, Parikh CR, Gordon K, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr. 2012;60(4):393–399.
   PubMed Web of Science ®Google Scholar
• Jung O, Haack HS, Buettner M, et al. Renal AA-amyloidosis in intravenous drug users–a role for HIV-infection?. BMC Nephrol. 2012;13:151.
   PubMed Web of Science ®Google Scholar
• Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.
   PubMed Web of Science ®Google Scholar
• Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10(5):309–315.
   PubMed Web of Science ®Google Scholar
• Peters L, Grint D, Lundgren JD, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26(15):1917–1926.
   PubMed Web of Science ®Google Scholar
• Lopes JA, Melo MJ, Viegas A, et al. Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. Nephrol Dial Transplant. 2011;26(12):3888–3894.
   PubMed Web of Science ®Google Scholar
• Soto K, Campos P, Pinto I, et al. The risk of chronic kidney disease and mortality are increased after community-acquired acute kidney injury. Kidney Int. 2016;90(5):1090–1099.
   PubMed Web of Science ®Google Scholar
• CKD evaluation & management | KDIGO [cited 2014 Jun 17]. Available from: http://kdigo.org/home/guidelines/ckd-evaluation-management/
   Google Scholar
• Lucas GM, Ross MJ, Stock PG, et al. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(9):e96-138.
   Google Scholar
• European AIDS Clinical Society. EACS Guidelines 8.0. 2016 Jun; Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• Prise en charge Médicale des personnes vivant avec le VIH recommandatiosn du groupe d’experts Rapport 2013 (Sous la direction du Pr Philippe Morlat) [Medical Management of people living with HIV: guideline] Available from: http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf
   Google Scholar
• Levey AS, De Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28.
   PubMed Web of Science ®Google Scholar
• Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011;79(8):825–842.
   PubMed Web of Science ®Google Scholar
• Levey AS, Becker C, Inker LA. Glomerular Filtration Rate and Albuminuria for Detection and Staging of Acute and Chronic Kidney Disease in Adults: A Systematic Review. JAMA. 2015;313(8):837–846.
   PubMed Web of Science ®Google Scholar
• Gagneux-Brunon A, Mariat C, Delanaye P. Cystatin C in HIV-Infected Patients: Promising but Not yet Ready for Prime Time. Nephrol Dial Transplant. 2012;27(4):1305–1313.
   PubMed Web of Science ®Google Scholar
• Ando M, Yanagisawa N, Ajisawa A, et al. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923–3929.
   PubMed Web of Science ®Google Scholar
• Ando M, Yanagisawa N, Ajisawa A, et al. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant. 2011;26:3224–3229.
   PubMed Web of Science ®Google Scholar
• Gravemann S, Brinkkoetter PT, Vehreschild JJ, et al. Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment. AIDS. 2014;28(12):1783–1789.
   PubMed Web of Science ®Google Scholar
• Reynes J, Cournil A, Peyriere H, et al. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2. AIDS. 2013;27(8):1295–1302.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Coresh J, Greene T, et al.. Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate. N Engl J Med. 2006;354(23):2473–2483.
   PubMed Web of Science ®Google Scholar
• Levey AS, Inker LA. GFR as the “Gold Standard”: Estimated, Measured, and True. Am J Kidney Dis. 2016;67(1):9–12.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Mariat C, Cavalier E, et al.. Trimethoprim, Creatinine and Creatinine-Based Equations. Nephron Clin Pract. 2011;119(3):c187–94.
   PubMedGoogle Scholar
• Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32(3):434–439.
   PubMed Web of Science ®Google Scholar
• Gutiérrez F, Fulladosa X, Barril G, et al.. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16(4):199–212.
   PubMed Web of Science ®Google Scholar
• Yombi JC, Pozniak A, Boffito M, et al.. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28(5):621–632.
   PubMed Web of Science ®Google Scholar
• Inker LA, Wyatt C, Creamer R, et al.. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr. 2012;61(3):302–309.
   PubMed Web of Science ®Google Scholar
• Praditpornsilpa K, Avihingsanon A, Chaiwatanarat T, et al.. Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients. AIDS. 2012;26(14):1781–1788.
   PubMed Web of Science ®Google Scholar
• Gagneux-Brunon A, Delanaye P, Maillard N, et al.. Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort. AIDS. 2013;27(10):1573–1581.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Mariat C, Maillard N, et al.. Are the creatinine-based equations accurate to estimate glomerular filtration rate in African American populations?. Clin J Am Soc Nephrol CJASN. 2011;6(4):906–912.
   PubMed Web of Science ®Google Scholar
• Driver TH, Scherzer R, Peralta CA, et al. Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women. AIDS. 2013;27(14):2291–2299.
   PubMed Web of Science ®Google Scholar
• Lucas G, Cozzi-Lepri A, Wyatt C, et al. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med. 2014;15(2):116–123.
   PubMed Web of Science ®Google Scholar
• Yanagisawa N, Sasaki S, Suganuma A, et al.. Comparison of cystatin C and creatinine to determine the incidence of composite adverse outcomes in HIV-infected individuals. J Infect Chemother. 2015;21(2):84–89.
   PubMed Web of Science ®Google Scholar
• Okparavero AA, Tighiouart H, Krishnasami Z, et al. Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. Antivir Ther. 2013;18(6):793–802.
   PubMed Web of Science ®Google Scholar
• Gagneux-Brunon A, Botelho-Nevers E, Delanaye P, et al. CKD-EPI equation: A suitable Glomerular Filtration Rate estimate for drug dosing in HIV-infected patients. Med Mal Infect. 2017;47:266–270.
   PubMed Web of Science ®Google Scholar
• Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when?. Clin Chim Acta. 2015 Jan;1(438):350–357.
   Web of Science ®Google Scholar
• Scherzer R, Lin H, Abraham A, et al.. Use of urine biomarker-derived clusters to predict the risk of chronic kidney disease and all-cause mortality in HIV-infected women. Nephrol Dial Transplant. 2016;31(9):1478–1485.
   PubMed Web of Science ®Google Scholar
• Maggi P, Montinaro V, Bellacosa C, et al. Early Markers of Tubular Dysfunction in Antiretroviral-Experienced HIV-Infected Patients Treated with Tenofovir Versus Abacavir. AIDS Patient Care STDs. 2011;26(1):5–11.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Shimbo T, Komatsu H, et al. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother. 2013;19(5):850–857.
   PubMed Web of Science ®Google Scholar
• Oboho I, Abraham AG, Benning L, et al. Tenofovir use and urinary biomarkers among HIV-infected women in the Women’s Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr. 2013;62(4):388–395.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Scherzer R, Abraham A, et al.. Urinary markers of kidney injury and kidney function decline in HIV-infected women. J Acquir Immune Defic Syndr. 2012;61(5):565–573.
   PubMed Web of Science ®Google Scholar
• Jotwani V, Scherzer R, Abraham A, et al. Association of urine α1-microglobulin with kidney function decline and mortality in HIV-infected women. Clin J Am Soc Nephrol CJASN. 2015;10(1):63–73.
   PubMed Web of Science ®Google Scholar
• Peralta C, Scherzer R, Grunfeld C, et al.. Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women’s Interagency HIV Study (WIHS). HIV Med. 2014 May;15(5):291–300.
   PubMed Web of Science ®Google Scholar
• Jaafar A, Séronie-Vivien S, Malard L, et al.. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS. 2009;23(2):257–259.
   Google Scholar
• Jotwani V, Scherzer R, Estrella MM, et al. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study. Am J Kidney Dis. 2016;68(4):571–581.
   PubMed Web of Science ®Google Scholar
• Ascher SB, Scherzer R, Peralta CA, et al.. Association of Kidney Function and Early Kidney Injury With Incident Hypertension in HIV-Infected Women Novelty and Significance. Hypertension. 2017;69(2):304–313.
   PubMed Web of Science ®Google Scholar
• Hall AM, Hendry BM, Nitsch D, et al.. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773–780.
   PubMed Web of Science ®Google Scholar
• Hikasa S, Yasuda M, Hideta K, et al.. The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients. Clin Exp Nephrol. 2016;19;1–7.
   Google Scholar
• Hall AM, Edwards SG, Lapsley M, et al.. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54(6):1034–1042.
   PubMed Web of Science ®Google Scholar
• Allavena C, Bach-Ngohou K, Billaud E, et al. Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen. J Antimicrob Chemother. 2013;68(12):2866–2870.
   PubMed Web of Science ®Google Scholar
• Gagneux-Brunon A, Botelho-Nevers E, Frésard A, et al.. Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment. AIDS. 2016;30(4):665–666.
   PubMed Web of Science ®Google Scholar
• Poizot-Martin I, Solas C, Allemand J, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2013;62(4):375–380.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Rosenblatt L, Myers J. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. HIV Clin Trials. 2016;17(6):246–266.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. N Engl J Med. 2013;369(19):1807–1818.
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49–57.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet. 2012;379(9835):2429–2438.
   PubMed Web of Science ®Google Scholar
• Mills A, Crofoot G, McDonald C, et al. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2015;69(4):439–445.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Ramgopal M, Crofoot G, et al. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017;4(5):e205–13.
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373(8):705–713.
   PubMed Web of Science ®Google Scholar
• Abraham AG, Darilay A, McKay H, et al. Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study. J Infect Dis. 2015;212(7):1100–1110.
   PubMed Web of Science ®Google Scholar
• Stein JH, Currier JS, Hsue PY. Arterial Disease in Patients With Human Immunodeficiency Virus Infection: What Has Imaging Taught Us?. JACC Cardiovasc Imaging. 2014;7(5):515–525.
   PubMed Web of Science ®Google Scholar
• Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric Dimethylarginine and Cardiovascular Risk: Systematic Review and Meta-Analysis of 22 Prospective Studies. J Am Heart Assoc. 2015;4(6):e001833.
   PubMed Web of Science ®Google Scholar
• Haissman JM, Haugaard AK, Knudsen A, et al. Marker of Endothelial Dysfunction Asymmetric Dimethylarginine Is Elevated in HIV Infection but Not Associated With Subclinical Atherosclerosis. J Acquir Immune Defic Syndr 1999. 2016;73(5):507–513.
   PubMed Web of Science ®Google Scholar
• Lutsey PL, Alonso A, Selvin E, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc. 2014;3(3):e000936.
   PubMed Web of Science ®Google Scholar
• Spagnuolo V, Cocorullo D, Galli L, et al. Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. J Antimicrob Chemother. 2013;68(12):2960–2963.
   PubMed Web of Science ®Google Scholar
• Atta MG, Estrella MM, Fine DM, et al. Correlates and Longitudinal Renal and Cardiovascular Implications of FGF23 Levels in HIV-Positive Individuals. PLOS ONE. 2016;11(5):e0155312.
   PubMed Web of Science ®Google Scholar
• 5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients - Full Text View - ClinicalTrials.gov [Internet]. [cited 2017 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02667678?term=kidney+and+HIV&rank=1
   Google Scholar
• Kandathil AJ, Sugawara S, Balagopal A Are T cells the only HIV-1 reservoir? Retrovirology [Internet]. 2016 Dec 20 [cited 2017 May 2];13. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175311/
   Google Scholar
• Ronco C, Rizo-Topete L, Serrano-Soto M, et al.. Pro: Prevention of acute kidney injury: time for teamwork and new biomarkers. Nephrol Dial Transplant. 2017;32(3):408–413.
   PubMed Web of Science ®Google Scholar